|
|
|
|
Vol. 62, Issue 4, 936-946, October 2002
Research Group Immunobiology (C.V.S., A.K., K.H., K.-D.K., V.K.-B.) and Institute of Pathology (C.M.), Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany; Neurologische Klinik der Ruprecht-Karls-Universität, Heidelberg, Germany (E.B.); and Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany (H.K., U.F.)
| |
Abstract |
|---|
|
|
|---|
We have investigated the impact of the widely used antifungal agent
Amphotericin B (AmB) on cytokine activated aortic endothelial cells
(AEC) and their inflammatory response as monitored by cytokine and
inducible nitric-oxide synthase (iNOS) expression as well as
high-output nitric oxide synthesis. Because both blood-borne infections
and systemically administered drugs will first encounter vessel lining
endothelial cells, this cell type represents an important participant
in innate immune reactions against xenobiotics. Culturing
cytokine-activated AEC in the presence of 1.25 µg/ml AmB, a
concentration equivalent to serum levels during patient treatment, we
find increases in iNOS promoter activity up to 120%, in iNOS mRNA or
protein expressions by factors of up to 3.5 ± 1.1, and in iNOS
activity of up to 180% compared with cells with cytokines only. In
parallel, a strong increase in endothelial interleukin
(IL)-1
-converting enzyme (ICE) and IL-1
expression and activity
was observed. Specific inhibition of ICE activity or IL-1
functionality significantly reduces expression and activity of the iNOS
to control values. Because ICE activity is essential for the endogenous
synthesis of active IL-1
, ICE overexpression represents the key
signal in the AmB-induced and IL-1
-mediated effects on iNOS
activity. In summary, in endothelial cells, AmB strongly augments
cytokine-induced iNOS expression and activity by increasing the
expression and activity of the ICE. This adjuvant activity for
augmented endogenous cytokine processing adds to the efficacy of the
antimycotic activity of AmB. Furthermore, our data underline the
relevance of the endothelial iNOS as a potent effector of the innate
immune system.
| |
Introduction |
|---|
|
|
|---|
Amphotericin
B (AmB) is a highly efficient antifungal drug widely used for systemic
infections (Gallis et al., 1990
). Along with the therapeutic efficacy
of AmB, serious toxicities are observed, among which nephrotoxicity as
a result of AmB-induced renal arteriolar vasoconstriction (Reiner and
Thompson, 1979
; Sawaya et al., 1991
) is the most important factor
limiting its use (Carlson and Condon, 1994
).
Despite its widespread use and clinical effectiveness, the mechanisms
of AmB antibiotic actions are still under investigation. Previously, it
has been observed that AmB potentiates the antimicrobial and
tumoricidal activities of macrophages (Perfect et al., 1987
), probably
via induction of cytokine synthesis, such as tumor necrosis factor-
(TNF-
) and interleukin-1
(IL-1
), as well as generation of a
respiratory burst (Wolf and Massof, 1990
). Antimicrobial defense of
macrophages includes synthesis of reactive oxygen species and nitric
oxide (NO) that contributes to the pathways by which cytokine- or
endotoxin-activated inflammatory cells mediate cytotoxic defense
against microbes (Nathan, 1992
). Chemically generated NO or its
derivatives (Alspaugh and Granger, 1991
) as well as NO derived from
macrophages (Cameron et al., 1990
), microglial cells (Blasi et al.,
1995
) or astrocytes (Lee et al., 1994
) has been shown to be fungistatic
or fungicidal. Recently, with murine macrophages, it has been shown
that AmB-induced increase in proinflammatory cytokine secretion are
responsible for augmenting their anticryptococcal activity through
triggering the NO-dependent pathway (Tohyama et al., 1996
).
The biochemical basis of NO-mediated effects involves inactivation of
enzymes essential for energy metabolism and growth (James, 1995
),
inhibition of the DNA binding activity of several transcription factors
(Kröncke et al., 1997
), but also NO-mediated
S-nitrosation of pathogenic viral, bacterial, fungal, and
parasitic cysteine proteinases (Venturin et al., 2000
), all of which
may represent general mechanisms of antimicrobial and antiparasitic
host defenses.
Endothelial cells display a capacity for cytokine synthesis similar to
that of macrophages and represent an equivalent source for NO
production by cytokine-induced expression of the inducible nitric-oxide
synthase (iNOS) (Suschek et al., 1993
). Because drugs administered via
the circulation will encounter the blood vessel lining endothelial
cells first before their transport into the tissue, we have focused on
the impact of AmB on iNOS expression and activity of cytokine-activated
endothelial cells. It has been shown that endothelial cell-derived,
high-output NO synthesis exhibits antiapoptotic and cell-protective
effects (Kim et al., 1999
; Suschek et al., 1999
). In addition,
cytokine-activated and iNOS-expressing endothelial cells were shown to
exert potent cytotoxic functions (Oswald et al., 1994
; Fehsel et al.,
1995
; Steiner et al., 1997
). Thus, although traditionally not
considered part of the immune system, endothelial cells may play an
important role in innate immunity and contribute to the resistance
against pathogens.
We here have tested the effects of AmB on iNOS mRNA expression and
enzyme activity as well as cytokine formation in primary cultures of
endothelial cells. Our experiments give further evidence for the
macrophage-like activity of endothelial cells in innate immune
responses and demonstrate that in activated endothelial cells, AmB
strongly augments nitric oxide production, exclusively because of
augmented interleukin-1
-converting enzyme (ICE) expression and
activity, which, via increases in endogenous bioactive IL-1
formation, further enhances iNOS expression and activity.
| |
Materials and Methods |
|---|
|
|
|---|
Reagents.
Recombinant human IL-1
and rat TNF-
was
purchased from HBT (Leiden, Netherlands); recombinant human or murine
-interferon (
-IFN) and recombinant human TNF-
were purchased
from Genzyme (Cambridge, MA). The ICE activity assay kit, polyclonal
anti-human-IL-1
and TNF-
antisera, monoclonal anti-rat-IL-
or
TNF-
antibodies and the rat IL-1
as well as rat TNF-
ELISA
kits from were from R & D Systems (Wiesbaden, Germany). Endothelial
cell growth supplement, LPS (from Salmonella typhimurium),
Neutral Red (3% solution), type I collagen, collagenase (from
Clostridium histolyticum), rabbit anti-human von Willebrand
Factor antiserum, and anti-
-tubulin antibody were from
Sigma-Aldrich (Deisenhofen, Germany). The rat endothelium specific
monoclonal antibody Ox43 was from Serotec (Camon, Wiesbaden, Germany).
The monoclonal anti-iNOS and anti-eNOS antibodies were from
Transduction Laboratories (Lexington, KY); peroxidase-conjugated
porcine anti-rabbit IgG was from DAKO (Hamburg, Germany);
peroxidase-conjugated goat anti-mouse IgG was from Zymed Laboratories
(South San Francisco, CA). Trypsin, EDTA, fetal calf serum (FCS,
endotoxin free) and Luciferase Assay Kit were from Roche Applied
Science (Mannheim, Germany); the caspase-inhibitor zVAD
was from Enzyme Systems (Livermore, CA) and the ICE-inhibitor YVAD was from Alexis (Läufelfingen, Switzerland). RPMI
1640 (endotoxin free), oligo(dT16)-primer, Taq DNA
polymerase, and amphotericin B (Fungizone) were from Invitrogen
(Eggenstein, Germany); 3,3'-diaminobenzidine was from Serva GmbH
(Heidelberg, Germany); and desoxycholate was from Squibb-Heyden
(Munich, Germany).
Cell Cultures.
Capillary islet endothelial cells (IEC) were
isolated from hand-picked pancreatic islets by outgrowth on a collagen
type I matrix as described previously (Suschek et al., 1994
), whereas rat aorta endothelial cells (AEC) were isolated by outgrowth from rat
aortic rings exactly as described previously (Suschek et al., 1994
).
Briefly, aortic segments or isolated whole islets were placed on top of
a collagen gel (1.8 mg/ml collagen) in 24-well tissue culture plates
and incubated in RPMI 1640 with 20% FCS and 100 µg/ml endothelial
cell growth supplement for 4 to 6 days depending on the degree of
cellular outgrowth. Aortic explants or islets were then removed, cells
were detached with 0.25% collagenase in Hanks' buffered saline
solution and replated onto plastic culture dishes in RPMI 1640/20%
FCS. Cells were subcultured for up to 10 passages, and removal from
culture dishes for each passage was performed by treatment with 0.05%
trypsin/0.02% EDTA in isotonic NaCl for 3 min. The human cell line
A549/8 was purchased from the American Type Culture Collection
(Manassas, VA).
Cellular Characterization of Cultured Cells.
Rat endothelial
cells (AEC, IEC) were characterized by using a cross reacting
rabbit-anti-human-von Willebrand Factor antiserum, the rat vascular
endothelium-specific monoclonal antibody Ox43, the rat thymocyte- and
brain endothelium-specific monoclonal antibody Ox2, and the respective
secondary peroxidase-conjugated porcine anti-rabbit IgG or
peroxidase-conjugated goat anti-mouse IgG antisera at conditions
exactly as described previously (Suschek et al., 1994
).
Experimental Design.
All measurements were performed with
cells from passages 2 to 8. Endothelial cells (1 × 105) were cultured in 12- or 24-well tissue
culture plates in 600 µl of RPMI 1640/20% FCS. Cytokine-challenge
was performed by addition of IL-1
, TNF-
, IFN-
, or LPS at
concentrations and combinations indicated, respectively. In addition,
endothelial cell cultures were incubated for 24 to 48 h with AmB,
the vehicle DOC, or the respective additives at concentrations
indicated. LPS concentrations of RPMI 1640 and FCS were below
0.1 µg/ml, and of cytokines, AmB, or DOC below 0.1 ng/µg, respectively.
Inhibition of Endogenous Endothelial IL-1
or TNF-
Expression or Activity.
Inhibition of endogenous bioactive IL-1
formation was achieved using the pan-caspase inhibitor ZVAD (30 µM)
or the specific ICE inhibitor YVAD (30 µM). Inhibition of endothelial
IL-1
activity or availability was achieved by addition of
neutralizing anti-rat-IL-1
antibodies [150 µg/ml with a
half-maximal neutralizing dose (ND50) of 20 µg/ml in the presence of ~1000 U/ml rat IL-1
] or neutralizing anti-human-IL-1
antibodies (100 µg/ml with an
ND50 of 0.2 µg/ml in the presence of ~500
U/ml recombinant human IL-1
), respectively. Endogenous endothelial
TNF-
production was inhibited by thalidomide (20 µg/ml) (Wnendt et
al., 1996
; Sastry, 1999
) or TNF-
activity was neutralized by
addition of anti-rat-TNF-
antibodies (150 µg/ml with an
ND50 of 25 µg/ml in the presence of 500 U/ml
rat TNF-
) or anti-human-TNF-
antibodies (25 µg/ml with an
ND50 of 0.01 µg/ml in the presence of 100 U/ml
recombinant human TNF-
), respectively. Specificity, as well as the
neutralizing effectiveness of the anti-rat-TNF-
antibody, was
characterized before its use (Table 1).
|
Nitrite Determination.
In experiments examining the effects
of AmB on endothelial high-output NO production by the iNOS, cells
(1 × 105 in 600 µl of medium) were
preincubated with AmB and the respective cytokines or additives at
concentrations indicated. Nitrite in culture supernatants accumulated
during the last 24 h was determined using the diazotization
reaction as described by Wood et al. (1990)
and
NaNO2 as standard.
Growth Rates of Cell Cultures and Viability. Cell growth was determined at different times by Neutral Red staining. Cells were incubated for 90 min with Neutral Red (1:100 dilution of a 3% solution), washed twice with PBS, dried completely, and lysed with isopropanol containing 0.5% 1 N HCl. Extinctions of the supernatants, which show a linear correlation to the cell number, were then measured at 530 nm. Additionally, viability of endothelial cells was controlled routinely at the beginning and end of every experiment using the trypan blue exclusion assay.
Polymerase Chain Reaction (PCR).
Total cellular RNA (1 µg
each) prepared from resting or cytokine-activated cells grown for
48 h in the presence or absence of AmB or DOC at concentrations
indicated was used for cDNA synthesis using the dT16-oligonucleotide as
primer. Reverse transcription was carried out at 42°C for 60 min. The
cDNA (500 ng each) was used as template for PCR primed by using the
oligonucleotides given in Table 2. PCR
was carried out following standard protocols with the following cycle
profiles: 25 cycles of 30 s at 94°C, 30 s at 60°C,
30 s at 72°C, and a final incubation step at 72°C for 10 min
for GAPDH-cDNA amplification; 35 cycles of 30 s at 94°C, 30 s at 60°C, 45 s at 72°C, and a final incubation step at 72°C
for 10 min for iNOS cDNA amplification; 30 cycles of 30 s at
94°C, 60 s at 60°C, 15 s at 72°C and a final incubation
step at 72°C for 10 min for rat TNF-
cDNA amplification; 32 cycles of 30 s at 94°C, 30 s at 58°C, 30 s at 72°C, and a
final incubation step at 72°C for 10 min for IL-1
cDNA
amplification; 34 cycles with 30 s at 94°C, 30 s at 56°C,
30 s at 72°C, and a final incubation step at 72°C for 10 min
for ICE cDNA amplification. Before PCR analysis, we routinely determine
the relative amount of the respective specific amplification product at
different PCR cycles and thus ensure that amplification conditions were
always within the linear phase. In some experiments, aliquots of iNOS
products were pooled with the GAPDH product and both were subjected to
electrophoresis on 1.8% agarose gels. Bands were visualized by
ethidium bromide staining. Densitometric analysis of the visualized
amplification products was performed by using the Kodak software
(Eastman Kodak, Stuttgart, Germany).
|
Sequence Analysis of the Amplified Rat mRNA Products.
PCR
products were purified via QIAGEN columns (QIAGEN, Hilden, Germany) and
cycle sequenced with the ABI BigDye Terminator Kit (Applied Biosystems,
Weiterstadt, Germany) using iNOS or IL-1
forward and reverse
amplification primers on an automated sequence analyzer (ABI 310 from
Applied Biosystems).
, rat ICE, or rat
TNF-
cDNA, respectively (data not shown).
Western Blot Analysis of the iNOS Protein.
Resting or
cytokine activated (200 U/ml IL-1
) AEC (7 × 106) were incubated for 48 h in the absence
or presence of 1.2, 2.5, or 5.0 µg/ml AmB. Using the NuPAGE
electrophoresis system (Invitrogen, Karlsruhe, Germany) endothelial
iNOS protein expression was examined exactly as we described previously
(Suschek et al., 2001
). Briefly, cultures were washed, scraped from the
dishes, lysed by the lauryl dodecyl sulfate sample buffer (4×),
transferred to a microcentrifuge tube, and boiled for 5 min. Proteins
(40 µg per lane) were separated by electrophoresis in a 12%-Bis-Tris
NuPAGE Novex precast polyacrylamide gel using the MOPS-SDS running
buffer system under reducing conditions (500 mM dithiothreitol) and
transferred to nitrocellulose membranes (Invitrogen) using the NuPAGE
transfer buffer (25 mM Bis-Tris, 25 mM Bicine, 1 mM EDTA, and 20%
methanol, pH 7.2) and following the manufacturer's instructions.
Further incubations of the blots were: 2 h with blocking buffer
(2% bovine serum albumin, 5% nonfat dry milk powder, 0.1% Tween 20 in PBS), 1 h at 37°C with a 1:2000 dilution of the monoclonal
anti-iNOS antibody, and 1 h with a 1:2000 dilution of the
secondary horseradish peroxidase-conjugated rabbit-anti-mouse-IgG
antibody. Finally, blots were incubated for 5 min in enhanced
chemiluminescence reagent (Pierce, Rockford, IL), and exposed to an
autoradiographic film. To control equal loading of total protein in all
lanes, blots were stained with a 1:2000 solution of the mouse
anti-
-tubulin antibody. Otherwise, conditions were as described
above. Densitometric analyses of the visualized iNOS protein or
-tubulin were performed by using the Kodak 1D software.
Detection of Endothelial IL-1
and TNF-
Production.
Resting or cytokine-activated (200 U/ml IL-1
) endothelial cells were
cultured in the presence or absence of AmB or the TNF-
synthase
inhibitor thalidomide at concentrations indicated. Thalidomide was present in culture supernatants 24 h before AmB challenge and
for the 24 h after incubation with AmB or was present only during
the 24 h of incubation with AmB. Then, in culture supernatants, the endothelial IL-1
or TNF-
production was assayed using the specific ELISA kits exactly as recommended by manufacturer. The species-specific anti-rat-cytokine antibodies used in the test do not
cross-react with human recombinant TNF-
that was used for cell
activation in our experiments. Testing the specificity of the rat
IL-1
ELISA kit, we found 0.36% cross-reactivity with human IL-1
.
Regarding this problem, rat cell culture supernatants containing the
added human IL-1
were examined by ELISA in parallel to pure medium
containing the same amount of the human cytokine, and values obtained
from these controls were subtracted from the values obtained with the
culture supernatants.
Detection of Endothelial ICE Activity. Endothelial ICE protein expression was determined as enzymatic activity of the caspase-1 protease using the caspase-1 colorimetric assay. The test is based on the principle that cells expressing ICE are first lysed to collect their intracellular contents. The cell lysate can then be tested for ICE activity by the addition of a ICE-specific peptide that is conjugated to the color reporter molecule p-nitroanaline. The cleavage of the peptide by the caspase releases the chromophore p-nitroanaline, which can be quantitated spectrophotometrically at a wavelength of 405 nm. The level of caspase enzymatic activity in the cell lysate is directly proportional to the color reaction.
Resting and cytokine-activated (single doses or combinations of 200 U/ml IL-1
, 500 U/ml TNF-
, and 500 U/ml IFN-
) endothelial cells
(1 × 106) grown for 24 h in the
presence or absence of 1.2 mg/ml AmB were harvested by trypsin
treatment and collected by centrifugation in a conical tube at
250g for 10 min. The supernatant was gently removed and
discarded, and the cell pellet was lysed by the addition of the lysis
buffer. The protein content of the cell lysates was estimated using a
protein determination assay (Pierce). The enzymatic reaction for
caspase activity was carried out in a 96-well, flat-bottomed microplate
that could be read with a microplate reader. If readings were not in
the linear range of the instrument, assay was repeated with diluted
cell lysates. Additional controls were probes with no cell lysate or no
substrate, respectively. The results were expressed as -fold increase
in caspase activity of AmB-treated cells over that grown in the absence
of AmB.
EPR Spectrometry.
For electron paramagnetic resonance (EPR)
spectrometric analysis of AmB effects on iNOS activity, we used rat IEC
because these cells, upon cytokine challenge, produce considerably more NO than other endothelial cell types (Suschek et al., 1994
). IEC were
cultured to near confluence in 10-cm dishes in RPMI 1640/20% FCS.
Cells were then incubated with or without 500U/ml TNF-
for 48 h
in the presence or absence of AmB (1.2 µg/ml). Cells (1 × 107) were harvested by EDTA/trypsin treatment,
washed twice with PBS, and transferred to quartz EPR tubes. After
centrifugation (250g for 3 min), tubes were stored in liquid
nitrogen. EPR spectra were taken using a computer controlled X-band
spectrometer (ESP 300; Bruker, Karlsruhe, Germany). All samples were
cooled to 90°K while recording the spectra. The machine parameters
used were: 10 mW of microwave power, 100-kHz modulation frequency,
7.55-G modulation amplitude, and a conversion time constant of
164 ms. The g-factor calibration was controlled using the
2,2'-diphenyl-1-picrylhydrazyl (DPH) radical signal at g = 2.0036.
Analysis of the Human iNOS Promoter Activity in Stably
iNOS-Transfected A549/8 cells.
To generate A549/8 cells stably
transfected with a construct containing a 16-kb fragment of the human
iNOS promoter cloned in front of a luciferase reporter gene, cells were
transfected by lipofection with
N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate according to the manufacturers recommendations using 4.5 mg of pNOS2(16)Luc (de Vera et al., 1996
) and 0.5 mg of pRc-CMV (Invitrogen) containing a neomycin resistance gene. The transfected cells were selected by G418-treatment (1 mg/ml). Different cell clones
were analyzed for luciferase activity and checked for integration of
the transfected DNA by PCR.
plus 1000 U/ml IFN-
, which was shown previously to lead to an increase in human iNOS promoter activity of ~2-fold. This represents about half-maximal induction of the iNOS-promoter-luc construct (de Vera et al., 1996Statistical Analysis. Values were derived from several individual experiments (n = 3-8) from cultures independently derived from different animals. Values were reported as mean ± S.D. For statistical analysis, we used analysis of variance followed by an appropriate post hoc multiple comparison test (Tukey method); p <0.05 was considered significant.
| |
Results |
|---|
|
|
|---|
Amphotericin B Toxicity in the Presence of Proinflammatory
Cytokines.
Incubation of AEC with IL-1
alone is a stimulus
sufficient for de novo endothelial iNOS expression and activity
(Suschek et al., 1993
, 1994
). Activated (200 U/ml IL-1
) AEC were
incubated with AmB or the vehicle DOC at concentrations indicated.
After 48 h of culture, the relative number of viable or dead cells
was determined using Neutral Red or trypan blue staining, respectively (Fig. 1). Incubation of
IL-1
-activated AEC with AmB at concentrations higher than 5 µg/ml
led to cell death in a dose-dependent manner. After 48 h of
incubation with 15 µg/ml AmB, only 5 ± 4% of the cells had
survived. Half-maximal cytotoxicity was found at 10.0 µg/ml AmB. We
therefore restricted our experiments using nontoxic concentrations of
AmB up to 5.0 µg/ml. Controls using the solvent DOC gave no effects.
Toxicity of AmB in the absence of cytokines was similar (Suschek et
al., 2000
) (data not shown).
|
iNOS mRNA and Protein Expression.
IL-1
(200 U/ml) activated
AEC were cultured in the presence or absence of AmB at
concentrations of 0.3 to 5.0 µg/ml. Reverse transcription and
polymerase chain reaction (RT-PCR) was performed with total RNA after
48 h of incubation.
alone led to endothelial de novo
iNOS mRNA expression at submaximal levels. Simultaneous presence of AmB
significantly augmented iNOS expression in a dose-dependent mode with a
maximal increase by the factor of 2.5 ± 0.25 at 1.2 µg/ml AmB
and a decrease at higher AmB concentrations (Fig.
2A), whereas the solvent alone was
without effects (Fig. 2B). AmB alone in the absence of the cytokine did
not result in de novo iNOS mRNA expression (Fig. 2C).
|
+ 1.2 µg/ml AmB led to a 3.8-fold increase in
iNOS protein levels compared with the IL-1
only treatment. Resting
cultures incubated with 1.2 µg/ml AmB only gave no positive signal
Fig. 3).
|
challenge only, we observed an increase during the
first 12 h to a level remaining constant for up to 48 h (Fig.
4A). In contrast, cells coincubated with
1.2 µg/ml AmB showed a constant increase in iNOS mRNA levels (Fig.
4B) throughout the observation period, resulting in significantly
higher levels at 36 and 48 h.
|
iNOS Enzyme Activity.
Next we examined whether AmB-mediated
increases in iNOS activity are found in combination with IL-1
only
or whether combinations with any proinflammatory stimulus will increase
iNOS-activity.
(Fig.
5A), 500 U/ml TNF-
(Fig. 5B), or 500 U/ml IFN-
+ 100 ng/ml LPS (Fig. 5C) in the presence of 0.3-1.2
µg/ml AmB led to a concentration-dependent increase in nitrite
concentrations in culture supernatants, which peaked at 1.2 µg/ml AmB
and was always significantly different from the cytokine and/or
DOC-only controls.
|
alone, which will not induce
iNOS expression or increased nitrite accumulation, as described
previously (Suschek et al., 1993
(100 U/ml) resulted in a 5-fold increase in iNOS
activity, a 3-fold increase with IL-1
(100 U/ml), and a 2-fold
increase with
-IFN + LPS (Fig. 6D).
|
|
Endothelial Cytokine and ICE Expression.
To elucidate the
enhancing effects of AmB on endothelial iNOS expression by using
specific PCR or ELISA, we then examined whether the AmB-induced
increases are caused by endogenous induction of the proinflammatory
cytokines IL-1
and/or TNF-
.
or TNF-
mRNA, cytokine challenge (200 U/ml
IL-1
) leads to both IL-1
- (2.4 ± 0.4-fold) and
TNF-
-specific mRNA (2.0 ± 0.1-fold) expression and both are
significantly increased in the additional presence of AmB (Fig.
8). Cytokine-specific ELISA measurement
of culture supernatants (Table 3 and Fig.
8B) from resting cells show that AmB does not influence TNF-
production but slightly increases endothelial IL-1
production
(4.2 ± 1.2-fold). Cytokine-challenge (200 U/ml IL-1
) of AEC
leads to high increases in IL-1
(13.8 ± 2.5-fold) and to some
TNF-
(2.5 ± 0.6-fold) production. In the additional presence
of AmB (1.2 µg/ml), formation of both cytokines was further augmented
(IL-1
, 36 ± 6.1-fold and TNF-
, 5.6 ± 1.3-fold over
production in resting cells), and TNF-
secretion was effectively
blocked by thalidomide (20 µg/ml).
|
|
Impact of Endothelial IL-1
and TNF-
Production on iNOS
Promoter Activity, iNOS-mRNA Expression, and iNOS Activity.
The
increases in iNOS mRNA expression (Figs. 2 and 4) after
coincubation of AEC with IL-1
+ 1.2 µg/ml AmB strongly correlate with increases in endothelial IL-1
or TNF-
expression (Fig. 8),
indicating that endogenous cytokine expression may be involved in
AmB-mediated enhancement of iNOS expression. We therefore analyzed the
effect of AmB as well as the impact of endothelial cytokine production
on iNOS promoter activity using the A549/8 cell line stably transfected
with a 16-kb fragment of the human iNOS promoter cloned in front of a
luciferase reporter gene (A549/8-iNOS-Luc) as well as iNOS-mRNA
expression and iNOS enzyme activity in AEC.
plus 1000 U/ml
IFN-
led to a half-maximal 2.1 ± 0.3-fold increase in iNOS promoter activity (Fig. 9A), whereas the
additional presence of AmB (1.2 µg/ml) led to a 4.6 ± 0.8-fold
increase, which represents the maximally possible activation level
achievable with this construct. These AmB-mediated increases in human
iNOS promoter activity were reduced to control levels (cytokines only)
in the presence of a neutralizing anti-human-IL-1
antibody.
Interestingly, the blocking of ICE activity by addition of the ICE
inhibitor YVAD was as effective as blocking IL-1
itself (Fig. 9A).
In contrast, neither the inhibition of endogenous TNF-
formation by
thalidomide nor neutralization with anti-human-TNF-
antibodies had
any influence on the AmB-induced increases in iNOS-promoter activity
(Fig. 9A).
|
but not TNF-
is the pivotal mediator
of AmB-induced effects on endothelial iNOS expression and activity.
The Dominant Role of Endothelial ICE Expression and Activity.
ICE activity represents a prerequisite for endogenous generation of
bioactive IL-1
(Watkins et al., 1999
). Therefore, we further
analyzed the role of endothelial ICE expression and activity on
AmB-induced iNOS overexpression. We find that under all conditions, in
resting and cytokine activated cells, AmB (1.2 µg/ml) strongly augments ICE mRNA expression (Fig. 10)
as well as ICE-enzyme activity (Table 4).
A careful investigation of the effects of ICE inhibition under the
various culture conditions was performed (Table 4). We find that
specific inhibition of ICE activity completely reverses the AmB-induced
iNOS overexpression as well as the increases in IL-1
formation.
Moreover, these data also reveal that ICE inhibition will completely
shut down iNOS expression in any condition that does not contain
exogenous IL-1
and will inhibit any additional AmB effects under all
conditions in which IL-1
was added. Thus these data demonstrate that
the main impact of AmB lies in the overexpression of ICE and any of the
other effects (i.e., increases in iNOS, IL-1
, or TNF-
) are an
indirect result of increased caspase-1 activity.
|
|
| |
Discussion |
|---|
|
|
|---|
The resistance to fungal infections is associated with
up-regulation of innate and acquired antifungal Th1-like responses, such as production of proinflammatory cytokines and NO. It has been
shown that a pharmacological inhibition of NO production greatly
reduces the resistance to fungal infections (Del Sero et al., 1999
).
AmB is a classic (and one of the most effective) antifungal drug
for the treatment of systemic fungal infections (Gallis et al., 1990
;
Carlson and Condon, 1994
). AmB may act directly on fungi by a mechanism
involving pore formation in fungal membranes (Clements and Peacock,
1990
; Gallis et al., 1990
) but has also been shown to increase the
NO-dependent anticryptococcal activity of macrophages, which correlated
with the endogenous production of proinflammatory cytokines (Tohyama et
al., 1996
).
After systemic application of AmB, in patients with cryptococcal
infections, serum concentrations of 1.0 to 3.0 µg/ml have to be
reached for drug efficacy (Louira, 1958
; Bindschadler and Bennett,
1969
; Fields et al., 1970
). AmB, systemically administered, will act
directly on the blood vessel lining endothelial cells; thus, this cell
population and its response to AmB are of prime interest. Recently, we
could show a concentration-dependent and biphasic effect of
amphotericin B on expression and activity of the constitutive eNOS in
resting aortic endothelial cells (Suschek et al., 2000
). With AmB at
clinically relevant concentrations, a highly significant increase in
eNOS activity was found, which may support the antithrombogenic state
of the endothelium and inhibit the trans-vascular migration
events of leukocytes or pathogens. In contrast, at higher AmB
concentrations, as are postulated to occur in the kidney because of
drug accumulation during therapy, a strong decrease in expression and
activity of the eNOS can be observed, an effect that will favor
thrombus formation and vasoconstriction, both potentially contributing
to the serious side effects observed during AmB therapy (Sawaya et al.,
1991
).
Migration of fungal pathogens across the endothelial cell layer is
considered a prerequisite for the organ invasion in systemic fungal
infections (Zink et al., 1996
). Activated endothelial cells are capable
of tumor cell killing as well as parasite, bacteria, virus, or tissue
destruction via the iNOS/NO pathway (Steiner et al., 1997
) and were
shown to augment the antifungal activity of polymorphonuclear cells
(Roseff and Levitz, 1993
). Endothelial cells have been shown to
synthesize NO in similar high-output concentrations as is known for
macrophages (Suschek et al., 1993
) and they express iNOS in vivo as a
consequence of cryptococcal infection (Goldman et al., 1996
). Thus,
endothelial cells will be involved in antifungal reactions.
Furthermore, as shown here with iNOS-expressing endothelial cells after
cytokine challenge, AmB exhibits a powerful enhancing activity on
iNOS-promoter as well as mRNA and protein expression and enzyme
activity, even in fully activated cells. These increases are paralleled
by a strongly enhanced endothelial production of the proinflammatory
cytokines IL-1
and TNF-
, which are known inducers/enhancers of
endothelial iNOS expression (Suschek et al., 1993
). Blocking the
formation or availability of IL-1
by specific antibodies completely
reverses AmB-induced effects on the iNOS, whereas inhibition of TNF-
formation or activity had no effect. Consequently, data presented give
evidence that with cytokine-activated endothelial cells, AmB-induced
increases in iNOS activity are dependent on either exogenously added or
produced IL-1
. Examining the events upstream of IL-1
formation,
we find that AmB-induced increases of bioactive IL-1
and iNOS can be completely blocked by the specific ICE inhibitor YVAD. Thus, for the
first time, we show herein that the core mechanism of AmB affecting
cytokine and iNOS expression is predominantly based on AmB-induced
increases in ICE activity.
The data presented here differ in important aspects from those of an
earlier study (Tohyama et al., 1996
), in which AmB at comparable
concentrations strongly augmented iNOS activities in IFN-
activated
mouse macrophages accompanied by augmented formation of IL-1
and
TNF-
. In this earlier study, an impact of both cytokines on the
AmB-induced iNOS increases activity had been postulated, due to
inhibition obtained by neutralizing antibodies. Interestingly, inhibition studies using neutralizing anti-TNF-
antibodies revealed a weak reduction of the AmB-induced effects on iNOS activity, and
IL-1
depletion led to an even more striking reduction of the
AmB-increased iNOS activity (Tohyama et al., 1996
). These results
indicate that in addition to induction of proinflammatory cytokine
synthesis, AmB may use additional or supplementary mechanisms to
influence iNOS expression and activity.
In contrast, we here now further support and underline previous
findings on the pivotal role of IL-1
in endothelial iNOS expression
(Suschek et al., 1993
; Bonmann et al., 1997
) and, in addition,
demonstrate for the first time the rate-limiting role for ICE activity
in iNOS expression. Thus, AmB-induced ICE increases will aid innate
responses, because IL-1
is involved not only in iNOS expression but
also induces endothelial adhesion molecules such as ICAM-1, VCAM-1, and
E-selectin, essential for leukocyte recruitment to sites of
inflammation, and induces or augments expression of other cytokines,
including TNF-
, IL-6, IL-8, MCP-1, and gro/MGSA, thereby adding to
proinflammatory and antifungal responses (Sahnoun et al., 1998
).
In conclusion, the experiments presented here show significant
AmB-induced increases in endothelial iNOS expression and activity in
cytokine-activated endothelial cells. These AmB-induced effects are
predominantly mediated by endogenous IL-1
formation because of the
action of AmB on expression and activity of ICE as a rate-limiting step
in IL-1
synthesis. Furthermore, these data underscore the relevance
and independent role of the vascular endothelium and endothelial iNOS
as potent machinery of the innate immune defense against microorganisms.
| |
Acknowledgments |
|---|
We thank Christa-Maria Wilkens-Roth, Ursula Lammersen, and Marija Lenzen for technical assistance.
| |
Footnotes |
|---|
Received April 15, 2002; Accepted July 12, 2002
This work was supported by grant SFB503 A3 from the Deutsche Forschungsgemeinschaft (to V.K.-B.).
Address correspondence to: Dr. Christoph V. Suschek, Research Group Immunobiology, Heinrich-Heine-University, P.O. Box 101007, D-40001 Düsseldorf, Germany. E-mail: suschek{at}uni-duesseldorf.de
| |
Abbreviations |
|---|
AmB, amphotericin B;
TNF, tumor necrosis
factor;
IL, interleukin;
iNOS, inducible nitric-oxide synthase;
ICE, interleukin-1
-converting enzyme;
IFN, interferon;
ELISA, enzyme-linked immunosorbent assay;
LPS, lipopolysaccharide;
eNOS, endothelial nitric-oxide synthase;
FCS, fetal calf serum;
RPMI, Roswell
Park Memorial Institute;
IEC, islet endothelial cells;
AEC, aorta
endothelial cells;
DOC, desoxycholate;
PBS, phosphate-buffered saline;
PCR, polymerase chain reaction;
GAPDH, glyceraldehyde-3-phosphate
dehydrogenase;
MOPS, 3-(N-morpholino)propanesulfonic
acid;
EPR, electron paramagnetic resonance;
kb, kilobase(s);
RT, reverse transcription;
NMA, NG-monomethyl-L-arginine;
YVAD, N-acetyl-Tyr-Val-Ala-Asp-aldehyde, an ICE inhibitor;
ZVAD, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone
pan-caspase inhibitor.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Falk, M. Hacham, A. Nyska, J. F. Foley, A. J. Domb, and I. Polacheck Induction of interleukin-1{beta}, tumour necrosis factor-{alpha} and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan J. Antimicrob. Chemother., May 1, 2005; 55(5): 713 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hemmrich, C. V. Suschek, G. Lerzynski, and V. Kolb-Bachofen iNOS activity is essential for endothelial stress gene expression protecting against oxidative damage J Appl Physiol, November 1, 2003; 95(5): 1937 - 1946. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||